Related Experiment Videos
Update on clinical trials of antiplatelet therapy for cerebrovascular diseases
D L Bhatt1, S R Kapadia, J S Yadav
1Departments of Cardiology and Neurology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Abstract:
Antiplatelet medications are an important part of the therapy of cerebrovascular diseases. Oral agents such as aspirin have an established role in the secondary prevention of stroke. An aspirin and dipyridamole combination has recently been approved. Ticlopidine has been proven to be more effective than aspirin, but its potentially serious side effect profile makes long-term use hazardous. Clopidogrel has been demonstrated to be both more effective than and at least as safe as aspirin. The combination of clopidogrel plus aspirin represents the likely future therapy for high-risk patients. The role of oral antiplatelet therapy in the acute treatment of stroke is beginning to be clarified. Aspirin treatment appears to be strongly indicated. Intravenous antiplatelet therapy with glycoprotein IIb/IIIa inhibitors for acute stroke and as an adjunct to carotid artery stenting appears promising.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clinical Trials: Overview
Peripheral Artery Disease III: Interprofessional Care
Clinical Trials
There are four phases in a clinical trial. A phase one...
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care